Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancerPIKTOR is an ...
Investing.com -- Sensei Biotherapeutics (NASDAQ:SNSE) stock soared 200% Wednesday after the company announced its acquisition ...
Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. | Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling ...
Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3Ka inhibitorData will include ...
Tech millionaire Bryan Johnson took to Instagram to share his thoughts on the newly released inverted food pyramid, a ...
Sensei Biotherapeutics, Inc. SNSE surged on Wednesday following the company’s announcement of its acquisition of Faeth Therapeutics Inc. and a concurrent $200 million private investment. The ...
Neurocrine Biosciences, Inc. leverages a strong cash position and a neuropsychiatry pipeline to drive long-term commercial ...
Asianet Newsable on MSN
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition
The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.
Chip’s deep experience commercializing significant oncology drugs will provide valuable insight to Celcuity as we advance our programs and prepare for the potential approval and launch of gedatolisib ...
Industry feedback confirms Rakovina's approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage ...
A large multiomics study of brain metastases identified four molecular subtypes shaped by the brain microenvironment, not tumor origin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results